Guidant’s last stand on paclitaxel
This article was originally published in The Gray Sheet
Company's paclitaxel-eluting stent program achieves closure with federal appeals court affirmation of lower court ruling that Cook's deal with Guidant violated a co-exclusive license agreement among Boston Scientific, Cook and Angiotech. The program already had been terminated due to poor DELIVER study results; in January, Guidant scuttled a proposed merger with Cook. Guidant is exploring an everolimus-eluting stent (1"The Gray Sheet" Jan 6, 2003, p. 4). Boston Scientific submits the fifth and final PMA module for its Taxus paclitaxel-eluting stent...
You may also be interested in...
Cook Group is considering re-starting the 1,200-patient, six-center PATENCY pivotal trial of its Logic PTX paclitaxel-eluting coronary stent
The company will use the proceeds to fund clinical trials, expand commercialization of its targeted radiation therapy, and file for CE marking in Europe.
Advanced Medical Solutions said it will buy Raleigh Adhesive Coatings for £22m ($29m) in cash to strengthen its overall wound care business.